PERSONALIS, INC.

(PSNL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Personalis Expects $20.7 Million in Revenue for Q4'21

01/06/2022 | 04:14pm EDT


© MT Newswires 2022
All news about PERSONALIS, INC.
04:33pPERSONALIS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/05Citigroup Adjusts Personalis' Price Target to $14 from $18, Keeps Buy Rating
MT
05/05HC Wainwright Adjusts Personalis' Price Target to $30 From $38, Reiterates Buy Rating
MT
05/04PERSONALIS : Q1 Earnings Snapshot
AQ
05/04TRANSCRIPT : Personalis, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04PERSONALIS, INC. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/04Personalis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/04Earnings Flash (PSNL) PERSONALIS Reports Q1 Revenue $15.2M, vs. Street Est of $14.4M
MT
05/04Personalis Reports First Quarter 2022 Financial Results
BU
05/04Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022
CI
More news
Analyst Recommendations on PERSONALIS, INC.
More recommendations
Financials (USD)
Sales 2022 64,4 M - -
Net income 2022 -113 M - -
Net cash 2022 161 M - -
P/E ratio 2022 -1,75x
Yield 2022 -
Capitalization 197 M 197 M -
EV / Sales 2022 0,56x
EV / Sales 2023 -0,21x
Nbr of Employees 326
Free-Float 97,9%
Chart PERSONALIS, INC.
Duration : Period :
Personalis, Inc. Technical Analysis Chart | PSNL | US71535D1063 | MarketScreener
Technical analysis trends PERSONALIS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 4,38 $
Average target price 17,50 $
Spread / Average Target 300%
EPS Revisions
Managers and Directors
John S. West President, Chief Executive Officer & Director
Aaron Tachibana Chief Financial Officer & Senior Vice President
Jonathan J. MacQuitty Chairman
Richard O. Chen Chief Medical Officer, SVP-Research & Development
Xavier Paliard Vice President-Immunology, Research & Development
Sector and Competitors
1st jan.Capi. (M$)
PERSONALIS, INC.-69.66%197
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524